Highlights in chronic myeloid leukaemia and myeloproliferative neoplasm

BJH - volume 13, issue 1, february 2022

D. Mazure MD


As every year, ASH 2021 brought us updates on current practice, new insights and promising future treatments. I have tried to select the most relevant data from the educational sessions and oral and poster abstracts that can influence our current and near-future practice in chronic myeloid leukaemia (CML) and myeloproliferative neoplasm (MPN).

(BELG J HEMATOL 2022;13(1):17–24)

Read more

Management of polycythemia vera: Recommendations from the BHS MPN subcommittee anno 2021

BJH - volume 12, issue 6, october 2021

C. Schuermans MD, D. Mazure MD, K. Van Eygen MD, L. Van Aelst MD, PhD, S. Benghiat Fleur MD, PhD, T. Devos MD, PhD


Polycythemia vera (PV) is classified by the World Health Organization (WHO) under the BCR-ABL-negative myeloproliferative neoplasms (MPNs) and is characterised by clonal proliferation of myeloid cells, which leads primarily to an increased red blood cell mass. Bone marrow morphology remains the cornerstone of diagnosis. Patients can present with thrombosis, microcirculatory symptoms, haemorrhage, splenomegaly, pruritus and other symptoms that reduce their quality of life and they are at risk of transformation to secondary myelofibrosis (MF) or acute myeloid leukaemia (AML). The main goal of therapy in PV is to minimise the thrombotic risk. To achieve this goal PV patients are being treated with low-dose aspirin and phlebotomies to reach a target haematocrit below 45%. In addition, high-risk patients are being treated with cytoreductive agents. Over the last years, new insights in the pathophysiology, diagnosis and prognosis of polycythemia vera were acquired and novel therapeutic options are available. In this paper we give an update on PV and provide diagnostic and therapeutic recommendations, taking into account the Belgian situation.

(BELG J HEMATOL 2021;12(6):258-74)

Read more

Belgian guidelines for diagnosis and treatment of chronic myelomonocytic leukaemia

BJH - 2021, issue 2, march 2021

M. Beckers MD, PhD, S. Sid MD, A. De Becker MD, B. Heyrman MD, N. Granacher MD, D. Mazure MD, S. Meers MD, PhD, M-C. Vekemans MD, PhD, On behalf of the other members of MDS and MPN committee


Chronic myelomonocytic leukaemia (CMML) is a rare haematological disease. Hallmark of the diagnosis is chronic monocytosis. Other clinical features include cytopenia, dysplasia with the associated complaints like fatigue or leucocytosis, splenomegaly with constitutional symptoms. Predicting prognosis and choosing the correct treatment can be challenging for the clinician. These guidelines cover the diagnosis and treatment of CMML and provide information on morphology, cytogenetics and molecular testing, clinical features including autoimmune manifestations, prognosis and risk assessment and a treatment algorithm for both the fit and unfit CMML patient.

(BELG J HEMATOL 2020;12(2):66-76)

Read more

P.28 Multiple myeloma with extramedullary anaplastic transformation: a case report

BJH - volume 11, issue Abstract Book BHS, february 2020

K. Voet , dr. J. Van Dorpe , P. Vlummens MD, D. Mazure MD

Read more

01 A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stromal cells after myeloablative or non-myeloablative conditioning in patients with haematological malignancies

BJH - volume 10, issue Abstract Book BHS, february 2019

A. De Becker MD, R. Schots MD, PhD, T. Kerre MD, PhD, D. Mazure MD, J. Maertens MD, PhD, E. Baudoux , C. Lechanteur , Y. Beguin MD, PhD

Read more

P34 A crépinette sign

BJH - 2018, issue Abstract Book BHS, february 2018

S. Kennes MD, T. Kerre MD, PhD, D. Mazure MD, P. De Visschere , C. De Vriendt

Read more

P.63 Successful treatment of late recurrence of mucormycosis with atypical presentation after haematopoietic stem cell transplantation

BJH - 2013, issue BHS Abstractbook, january 2013

D. Mazure MD, L. Noens MD, PhD, T. Kerre MD, PhD

Read more